Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA

Autor: Joseph P. Garay, Rebecca Smith, Kaylyn Devlin, Daniel P. Hollern, Tiera Liby, Moqing Liu, Shanta Boddapati, Spencer S. Watson, Amanda Esch, Ting Zheng, Wallace Thompson, Darcie Babcock, Sunjong Kwon, Koei Chin, Laura Heiser, Joe W. Gray, James E. Korkola

Publikováno v: Breast Cancer Research, Vol 23, Iss 1, Pp 1-17 (2021)

Abstract Background HER2-amplified breast cancer is a clinically defined subtype of breast cancer for which there are multiple viable targeted therapies. Resistance to these targeted therapies is a common problem, but the mechanisms by which resistan

Externí odkaz: https://doaj.org/article/8c8e2b0cbc1d479e8a286db82615c089

CRISPR‐based knock‐in mutagenesis of the pioneer transcription factor FOXA1: optimization of strategies for multi‐allelic proteins in cancer cells

Autor: Shen Li, Joseph P. Garay, Colby A. Tubbs, Hector L. Franco

Publikováno v: FEBS Open Bio, Vol 11, Iss 6, Pp 1537-1551 (2021)

Precise genome engineering of living cells has been revolutionized by the introduction of the highly specific and easily programmable properties of the clustered regularly interspaced short palindromic repeats (CRISPR) technology. This has greatly ac

Externí odkaz: https://doaj.org/article/ba9a01acea6c4776a594080b4e3dd4f2

Supplementary Figures 1 - 8 from Single Copies of Mutant KRAS and Mutant PIK3CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation

Autor: Ben Ho Park, Josh Lauring, Pedram Argani, Yoshitaka Hosokawa, Akinobu Ota, Yuko Konishi, Sivasundaram Karnan, Rory L. Cochran, Sarah Croessmann, Danijela Jelovac, Justin Cidado, Michaela J. Higgins, Morassa Mohseni, Joseph P. Garay, William Matsui, Zeshaan Rasheed, Samuel Ray Denmeade, D. Marc Rosen, John P. Gustin, Abde M. Abukhdeir, Brian G. Blair, Hiroyuki Konishi, Hong Yuen Wong, Grace M. Wang

PDF file - 1480K, Figure S1. Double knock in clones have single mutant PIK3CA alleles and equivalent expression of mutant and wild type PIK3CA and form aberrant structures in 3D culture. Figure S2. DKI xenografts retain the same number of KRAS and PI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cbb464b436aa1e0e0399e735863603e
https://doi.org/10.1158/0008-5472.22397007

Data from Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-ras–Mediated Transformation

Autor: Ben Ho Park, Kurtis E. Bachman, Eike Gallmeier, Yuko Konishi, Joseph P. Garay, John P. Gustin, Josh Lauring, Abde M. Abukhdeir, Bedri Karakas, Hiroyuki Konishi

The oncogenic function of mutant ras in mammalian cells has been extensively investigated using multiple human and animal models. These systems include overexpression of exogenous mutant ras transgenes, conditionally expressed knock-in mouse models,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a0660684f5aab2324d406106c5e665
https://doi.org/10.1158/0008-5472.c.6495501.v1

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

Autor: Federico Rojo, Kevin R. Mott, Jeffery M. Rosen, Juan Miguel Cejalvo, Octavio Burgues, Susana García-Recio, Lisa A. Carey, Aleix Prat, Eduardo Martínez de Dueñas, Fara Brasó-Maristany, Alisha R. Coffey, Joel S. Parker, Ana Lluch, Xiaping He, Sara R. Selitsky, Charles M. Perou, Cheng Fan, Daniel P. Hollern, Joseph P. Garay, Michael P. East, Aatish Thennavan, Patricia Galván, David Marron, Joan Albanell, Gary L. Johnson

Publikováno v: J Clin Invest
JOURNAL OF CLINICAL INVESTIGATION
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón

Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a2898dd5990fe2b6e45febf0697a72
https://doi.org/10.1172/jci130323